Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
VACCINEX, INC. (VCNX)
|
Add to portfolio |
|
|
|
| Price: |
$1.11
| | Metrics |
| OS: |
65.9
|
M
| |
|
|
| Market cap: |
$73.2
|
M
| |
|
|
|
Net cash:
|
$1.77
|
M
| |
$0.03
|
per share
|
|
EV:
|
$71.4
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($22.0)
|
M
| |
|
|
|
EBIT
|
($22.0)
|
M
| |
|
|
| EPS |
$0.12
| |
9.3
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 0.3 | 0.9 | 0.6 | 0.5 | 0.7 | 0.1 | 0.3 |
| Revenue growth | -69.4% | 44.0% | 19.5% | -27.8% | 704.4% | -71.5% | |
| Cost of goods sold | 20.2 | 23.4 | 0.0 | 0.2 | 1.0 | 0.2 | 0.1 |
| Gross profit | -19.9 | -22.5 | 0.6 | 0.3 | -0.3 | -0.1 | 0.2 |
| Gross margin | -7238.5% | -2498.9% | 99.7% | 62.0% | -42.7% | -77.8% | 63.6% |
| Selling, general and administrative | 0.0 | 0.0 | | | | | |
| Research and development | | | 21.5 | 25.7 | 22.4 | 16.6 | 16.0 |
| General and administrative | 0.0 | 0.0 | 7.4 | 6.7 | 4.6 | 4.5 | 4.4 |
| EBIT | -19.9 | -22.5 | -28.3 | -32.0 | -27.3 | -21.1 | -20.3 |
| EBIT margin | -7238.5% | -2498.9% | -4533.0% | -6121.4% | -3768.1% | -23448.9% | -6411.1% |
| Pre-tax income | -19.8 | -22.4 | -28.9 | -31.9 | -29.5 | -18.8 | -13.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 0.0 | 0.0 | -28.9 | -31.9 | -29.5 | -18.7 | -13.9 |
| Net margin | 0.0% | 0.0% | -4616.2% | -6092.4% | -4077.1% | -20802.2% | -4412.3% |
| |
| Diluted EPS | $0.00 | $0.00 | ($1.54) | ($2.47) | ($5.65) | ($16.99) | ($26,233.00) |
| Shares outstanding (diluted) | 42.4 | 28.8 | 18.8 | 12.9 | 5.2 | 1.1 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|